Gluetacs was honored with the “Future Star Alumni Enterprise Award” at the 6th University of Chinese Academy of Sciences (UCAS) Alumni Innovation Forum.

ON：2025-5-27 TAGS：GLUETACS THERAPEUTICS

Gluetacs was honored with the “Future Star Alumni Enterprise Award” at 2025’s forum

On the afternoon of May 24, 2025, the 6th University of Chinese Academy of Sciences (UCAS) Alumni Innovation Forum was successfully held in Beijing. Under the theme “Empowering Alumni, Achieving Excellence”, the forum brought together leading figures from academia and industry. As a pioneer in the field of innovative protein degradation drugs, Gluetacs’ founder and CEO, Dr. Xiaobao Yang, is an alumnus of the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. Recommended by the Shanghai Alumni Association of the University of Chinese Academy of Sciences, he was honored with the “Future Star Alumni Enterprise Award” at this year’s forum.

The “Future Star Alumni Enterprise Award“ recognizes outstanding companies with valuations between 500 million to 1.5 billion RMB, representing the driving force of China’s new economy. This accolade not only affirms Gluetacs’ technological leadership and commercialization potential but also underscores UCAS’ strong support for alumni-led innovation. Inspired by UCAS’ principle of “integrating science and education,” Gluetacs remains committed to addressing unmet clinical needs through cutting-edge science. Moving forward, the company will continue collaborating with the UCAS alumni network to accelerate breakthroughs in industrializing protein degradation drugs.